1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Middle East and Africa Non-Alcoholic Steatohepatitis Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Middle East and Africa Non-Alcoholic Steatohepatitis Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Middle East and Africa Non-Alcoholic Steatohepatitis Market Regional Analysis
6.2 Middle East and Africa Non-Alcoholic Steatohepatitis Market Revenue 2019-2028 (US$ Million)
6.3 Middle East and Africa Non-Alcoholic Steatohepatitis Market Forecast Analysis
7. Middle East and Africa Non-Alcoholic Steatohepatitis Market Analysis – by Product
7.1 Vitamin E and Pioglitazone
- 7.1.1 Overview
- 7.1.2 Vitamin E and Pioglitazone: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Ocaliva
- 7.2.1 Overview
- 7.2.2 Ocaliva: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Elafibranor
- 7.3.1 Overview
- 7.3.2 Elafibranor: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Selonsertib
- 7.4.1 Overview
- 7.4.2 Selonsertib: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.5 Cenicriviroc
- 7.5.1 Overview
- 7.5.2 Cenicriviroc: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. Middle East and Africa Non-Alcoholic Steatohepatitis Market Analysis – by Application
8.1 Treatment
- 8.1.1 Overview
- 8.1.2 Treatment: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Diagnosis
- 8.2.1 Overview
- 8.2.2 Diagnosis: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. Middle East and Africa Non-Alcoholic Steatohepatitis Market Analysis – by Sales Channel
9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Online Provider
- 9.2.1 Overview
- 9.2.2 Online Provider: Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 Retail Pharmacy
- 9.3.1 Overview
- 9.3.2 Retail Pharmacy : Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. Middle East and Africa Non-Alcoholic Steatohepatitis Market – Middle East and Africa Analysis
10.1 Overview
10.2 Middle East and Africa
- 10.2.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 10.2.1.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 South Africa:
Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.1.1 South Africa: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Product
- 10.2.1.1.2 South Africa: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Application
- 10.2.1.1.3 South Africa: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel
- 10.2.1.2 Saudi Arabia:
Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.2.1 Saudi Arabia: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Product
- 10.2.1.2.2 Saudi Arabia: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Application
- 10.2.1.2.3 Saudi Arabia: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel
- 10.2.1.3 UAE:
Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.3.1 UAE: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Product
- 10.2.1.3.2 UAE: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Application
- 10.2.1.3.3 UAE: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel
- 10.2.1.4 Rest of Middle East and Africa:
Middle East and Africa Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.4.1 Rest of Middle East and Africa: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Product
- 10.2.1.4.2 Rest of Middle East and Africa: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Application
- 10.2.1.4.3 Rest of Middle East and Africa: Middle East and Africa Non-Alcoholic Steatohepatitis Market Breakdown, by Sales Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Cadila Pharmaceutical.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Intercept Pharmaceutical.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Galmed Pharmaceutical.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GENFIT.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Siemens Healthineers AG.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Laboratory Corporation of America Holdings.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations